AstraZeneca hands Compugen $10M to launch I/O discovery deal; RA Capital joins opposition to proposed BioCryst/Idera merger
→ Israel’s Compugen $CGEN nabbed a $10 million upfront to get started on a discovery deal with AstraZeneca on bi- and multi-specific antibodies for immuno-oncology. The pharma giant also committed to $200 million in milestones. “This licensing deal allows us to monetize specific scientific advances in our programs, while we continue to advance our lead programs into clinical trials,” said Compugen CEO Anat Cohen-Dayag.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
